Please login to the form below

Not currently logged in

Meet the Judges

The PMEA judging panel comprises a range of experts with a breadth of knowledge and experience, from pharmaceutical marketing specialists to leading management consultants to top business school academics.

Simon Bates

Simon Bates is a partner in PA Consulting’s life sciences team, where he works with major global pharma and medtech scale-up clients. He leads PA’s capabilities in digital health. In the life sciences sector, he has worked on many innovative programs to launch and optimise patient- and HCP-facing digital ecosystems. These have spanned sales & marketing, medical & scientific education, and therapy/diagnostic support touchpoints.  He has a deep appreciation of the complex healthcare context, its regulatory framework and its need to re-invent how actors in the ecosystem work together to drive value. He has also worked on customer-centric, data-led and omnichannel strategies in sectors such as consumer, retail, financial services, automotive, utilities and government. He has a passion to help healthcare & life science organisations harness the best of all the digital-age patterns and technology capabilities to improve outcomes for patients.

Richard Bartlett

Richard Bartlett is an associate partner at McKinsey & Company in London and a leader in McKinsey’s Medical Products practice and leads McKinsey’s transformation work in Medical Products across Europe. He serves medical product companies on holistics transformation, commercial excellence and strategy predominantly in Europe. In addition, Richard serves clients across both the public and private sector in healthcare, focusing on health system strategy and reform, new model of care design, and integrated care.

Paula Bellostas Muguerza

Paula Bellostas Muguerza, partner, Pharmaceutical & Healthcare Team, Kearney. Paula leads the European pharmaceutical and healthcare practice. She has consulted for nearly a decade in the pharmaceutical industry, helping pharmaceutical and biopharmaceutical clients formulate strategic responses to changes in the healthcare environment, regularly working with senior management teams. Her current area of interest is understanding the threats and opportunities that digital technologies bring to the pharmaceutical value chain. She has contributed to many industry articles and is a non-executive director for a digital health start-up that focuses on using digital technologies to achieve sustainable human performance.
Outside of Kearney, Paula is an ambassador for the Samaritans charity working on corporate outreach and is an active blogger on mental health in the workplace.

Antony Faupel

Antony Faupelis a senior bio-pharmaceutical commercial executive with European and Global strategic marketing management background. He has significant UK experience with GlaxoSmithKline and MSD in most therapeutic areas and, also, in specialist and rare diseases with Takeda Europe and Shire Global.  Anthony has extensively participated in major marketing and sales excellence programmes, along with substantial new product development activity; notably launch experience in migraine, emesis, cardiovascular, asthma, diabetes and oncology therapy areas.  His experience includes management oversight of numerous cross-functional, matrix and business process redesign teams.

Mark Flannagan

Mark Flannagan joined Alder Hey Children’s NHS Foundation Trust in July 2017 from Beating Bowel Cancer, where had been Chief Executive since 2010.  He has an extensive career in Board level health communications, including at the Royal College of General Practitioners; the Royal College of Nursing and Diabetes UK.  Mark has also in BBC Communications during a period of major change and challenge to the Corporation.

He has direct experience of handling crisis communications, not just during the Covid pandemic, and an internationally high-profile case in early 2018, but in many other cases.  Mark has also been a Trustee of different charities covering environmental issues and support families in need.

A keen road cyclist Mark has raised money for charities by taking part in cycling challenges, including Ride London 100, and cycling from London to Paris.

Karen Fraser

Karen Fraser is managing director of Acuitas, a consultancy providing astute commercial insight and international KOL perspective to the biopharma and investment communities. She has over 35 years' industry experience, which includes senior sales and marketing positions in companies such as Amersham International, Glaxo Laboratories and Lorex Synthélabo. Karen also set up a successful marketing consultancy specialising in the provision of commercial planning and implementation for companies wishing to enter the UK market. Prior to setting up Acuitas, she spent 15 years as vice president at Quintiles, providing marketing and therapeutic insight to support global Due Diligence and Business Development activities.

Kate Gribbon

Kate Gribbonhas more than 20 years’ experience in the Pharmaceutical and Healthcare Industry in Sales, Training and Sales Management although most of her career focused on Marketing, both in the UK and in Europe.

Her most recent role as Head of Rare Diseases afforded her the opportunity to really develop strategies to ensure the patient was at the heart of all marketing activities. She also developed campaigns to utilize RWE to support diagnostic initiatives challenging HCPs in their diagnosis of patients with Rare metabolic conditions.

Kate recognizes the value of teams –both cross functional internal teams and extended external agency support to develop compelling, meaningful and successful campaigns that support Clinicians in delivering the best patient outcomes.

Stephanie Hall

Stephanie Hall is the founder and Managing Director of Uptake Strategies, an award-winning global healthcare consultancy specialising in planning, capability and launch. Stephanie has been recognized as one of the UK’s top 10 women entrepreneurs in EY’s Winning Women Entrepreneurs’ programme in 2019 and won the International category at the 2020/21 National Businesswomen’s awards.

As a chartered management accountant and a chartered marketer and with a degree in French and Italian, Stephanie brings a unique approach to solving your business challenges. Stephanie has over 25+ years’ experience in marketing, finance, sales roles and consultancy projects in multi-national pharma/biotech companies (GSK, Eli Lilly & Co, Sanofi) and alliance partnerships.

Stephanie speaks regularly at industry conferences and is the author of the Pharma Brand Planners’ blog, Launch Leaders’ blog and Pharma Marketers’ blog in Pharma Marketing Europe and

Therapeutic experience spans the major diagnoses e.g. cardiology, respiratory, neuroscience, obesity, oncology, diabetes, rare diseases, dermatology and ADHD.

Stephanie describes herself as strategic, driven, passionate about healthcare marketing and fascinated by new challenges, international cultures and entrepreneurship.

Roz Lawson

Roz Lawson has led consultancy projects with companies across the pharma, biotech and medtech sectors for more than 15 years. She helps clients optimise the launch of new products and drive portfolio growth, through opportunity assessment, commercial model design, launch strategy and in-market effectiveness.

She has worked across the product lifecycle at European, global and country levels, and in Rx, B2B and B2C settings and has broad therapeutic area experience, with particular focus on oncology, rare diseases, diabetes and women’s health.

Roz started her working life in pharmaceutical sales, before gaining significant experience in brand marketing at European and global levels for assets in Phase 2, pre-launch, launch phase and facing LOE.

She started as a PMEA judge in 2020 and is excited to see the entries for 2021

Giorgia Leoni

Giorgia Leoni is one of EY’s Global Commercial Strategy Leaders in Life Sciences. She spent her career in consulting, primarily in pricing and market access strategy, for many years to later focus on business model innovation and outcomes based models. Throughout her career, Giorgia supported top life sciences companies with the launch strategy of their key assets and has recently won the Management Consultancies Association (MCA) Award for best International project for EY’s work with AstraZeneca on their first digital therapeutic.

Giorgia is passionate about the diversity and inclusiveness agenda and held pivotal roles within the Healthcare Businesswomen Association for several years.

Alasdair Mackintosh

Alasdair Mackintosh is director and founder, Keyhaven Associates Ltd. He is a senior business advisor and independent strategy and transformation consultant with extensive experience in the healthcare sector. He is also a Trustee and Vice Chair of the Pituitary Foundation, a patient-focused charity which provides essential information and support for people diagnosed with a range of pituitary disorders.

Over the past 24 years, Alasdair has supported many major healthcare organisations to enhance their commercial performance, develop effective digital strategies, and deliver better health outcomes for patients. He also helps entrepreneurs and investors in smaller, emerging enterprises to assess expansion opportunities, strengthen their business processes and governance, and to build effective organisations.

Alasdair was previously a partner and member of the global leadership teams at PA, Eden McCallum, Archstone and Gemini Consulting. He has an MSc in Business Management from the University of London and is a Sloan Fellow of the London Business School.

Thalita Marinho

Thalita Marinho is a Director in the Strategy Team of PricewaterhouseCoopers. She has 14 years of industry and consulting experience in the pharmaceutical and energy sectors. She worked at Royal Dutch Shell in Strategy and Economic valuation roles. She then joined Booz & Company, a strategic management consultancy, where she focused on commercial strategy in the Pharma and Life sciences sector.

At PwC, Thalita works closely with global pharma leaders to develop and implement corporate and business level strategy. She leads projects on topics across the pharma value chain, including Sale & Marketing, Market Access & Pricing, and Patient Centricity. Her clients include Big Pharma, biotechs, generics, OTC and healthcare distributors.

Thalita has an MBA from the London Business School and is an Economist.

Craig Mills

Craig Mills is Founder, of Frontera Group. He is the Group’s Head of Strategy with over 20 years’ experience in the healthcare sector. Craig is a judge and business leader on the entrepreneurship programme, Bright Ideas at Kingston University, London. He is also an active supporter of the Pathway - the Faculty for Homeless and Inclusion Health, which seeks to transform health outcomes for one of societies most deprived groups.

Over the past 20+ years, Craig has led healthcare organisations driving their commercial performance, by helping them to develop strategies that centre on the patient’s experience of health. Today he runs a group of 3 agencies focused on the acquisition of real world evidence and, in partnership with academic teams, including Imperial College and University of Cambridge, supporting organisations in the adoption of behavioural theory to bring about the change they seek.

Paul Simpson

Paul Simpson is the Head of Contract Sales and Medical Solutions at IQVIA UK.

He has extensive pan-European and US experience of pharma/biotech commercialisation and has held senior roles in marketing, sales and general management.

Paul is a staunch advocate of account management, using environmental understanding to derive practical solutions which help clients drive healthcare forward and ultimately lead to better outcomes for patients.

Dr Paul Stuart-Kregor

Dr Paul Stuart-Kregor is one of the three founders of The CELLO Health Consultancy and has worked in pharmaceuticals for 30 years, both client side and consultancy.

Paul has wide-ranging pharmaceutical, OTC and consumer marketing experience in UK and overseas, with expertise focused in the areas of market scoping and market insight for new and existing therapy areas, marketing strategy (Phase II to in-market compounds), brand development/repositioning, organisational design and process development plus marketing and operational excellence.

His focus now also includes mentoring future business leaders and working with start ups.

He holds an MA from Cambridge University and a PhD in Reproductive Endocrinology. He has been extensively published across a range of industry journals.


Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022